Edition:
United States

Profile: Titan Pharmaceuticals Inc (TTNP.A)

TTNP.A on American Stock Exchange

0.48USD
16 Aug 2019
Change (% chg)

-- (--)
Prev Close
$0.48
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
523
52-wk High
$3.63
52-wk Low
$0.48

Titan Pharmaceuticals, Inc. (Titan), incorporated on February 7, 1992, is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. The Company's drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson's disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism. The Company is engaged in the development of Probuphine for the maintenance treatment of opioid dependence. Probuphine utilizes ProNeura, Titan's long-term drug delivery platform. Upon subdermal insertion in a patient, Probuphine is designed to release medication and maintains an around the clock blood level of the drug buprenorphine, an approved agent for the treatment of opioid dependence. Probuphine is in Phase III clinical study stage.

The Company's ProNeura drug delivery technology provides a clinically-validated platform to provide continuous dopaminergic stimulation (CDS) for months from a single treatment. The Company has conducted preliminary experiments to investigate the use of its ProNeura technology to deliver dopamine agonists for the treatment of PD. The Ropinirole implant is a subdermal implant utilizing Titan's ProNeura drug delivery platform. The Ropinirole implant can deliver continuous, non-fluctuating levels of this dopamine agonist in order to provide continuous dopaminergic stimulation (CDS) for a minimum of over three months and six months or longer, from a single treatment. The Company's Once-daily synthetic T3 (Cytomel) is a medication for hypothyroidism but can cause side effects, such as headache, nervousness, irritability, sweating and cardiac arrhythmias, which are caused by the peak-and-trough blood-level fluctuations of T3 associated with standard oral delivery. The T3 implant is a subdermal implant utilizing Titan's ProNeura drug delivery platform. It can offer continuous delivery of T3 for patients who need it in their hypothyroidism treatment regimen.

The Company competes with Indivior, PLC, GlaxoSmithKline, US WorldMeds LLC, Novartis Pharmaceuticals Inc., Boehringer Ingelheim Pharmaceuticals Inc., UCB Inc, Pfizer, Coastal Pharmaceuticals, Mylan and Sigma Pharmaceuticals.

Company Address

Titan Pharmaceuticals Inc

400 Oyster Point Blvd Ste 505
SOUTH SAN FRANCISCO   CA   94080-1958
P: +1650.2444990
F: +1650.2444956

Company Web Links